Industry News Archive

FDA Approves Cemiplimab + Chemotherapy for NSCLC

On November 8, 2022, the U.S Food and Drug Administration (FDA) approved cemiplimab-rwlc in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.

For more information, read the FDA Announcement and the Regeneron press release.

Posted 11/9/2022


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
tacos-oncology.com
Email Us